SequelSEC

BURZYNSKI RESEARCH INSTITUTE INC BZYR

In Vitro & In Vivo Diagnostic Substances · CIK 0000724445 · Fiscal year ends 0228

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-02-28
Operating income
-$1.39M
Fiscal year ended 2025-02-28
Free cash flow
Unavailable
Fiscal year ended 2025-02-28

BURZYNSKI RESEARCH INSTITUTE INC (BZYR) reported revenue of $0 and net income of -$1.39M for the fiscal year ended 2025-02-28. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BURZYNSKI RESEARCH INSTITUTE INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

BURZYNSKI RESEARCH INSTITUTE INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-02-282024-02-292023-02-282022-02-282021-02-282020-02-292019-02-282018-02-282017-02-282016-02-29
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$1.39M-$1.34M-$916.29K-$976.66K-$1.30M-$1.63M-$1.64M-$1.61M-$1.50M-$2.01M
Net income-$1.39M-$1.34M-$916.29KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Research & development$1.05M$865.00K$718.50K$759.51K$1.02M$1.20M$1.15M$1.28M$1.32M$1.85M
Weighted-average diluted sharesshares 131.45Mshares 131.45Mshares 131.45Mshares 131.45Mshares 131.45MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$1.39M-$1.34M-$916.29K-$976.66K-$1.20M-$1.63M-$1.64M-$1.61M-$1.50M-$2.01M
Income tax expense$0$0$0$0$0$0UnavailableUnavailableUnavailable$0
Diluted EPS$-0.01$-0.01$-0.01$-0.01$-0.01UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$340.27K$470.43K$197.79K$217.15K$278.82K$431.78K$491.78K$332.63K$179.07K$157.07K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BURZYNSKI RESEARCH INSTITUTE INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-02-282024-02-292023-02-282022-02-282021-02-282020-02-292019-02-282018-02-282017-02-282016-02-29
Cash & equivalents$847$1.31K$934$3.38K$62$163$708$506$731$3.30K
Total assets$847$2.31K$1.93K$4.66K$956$19.85K$22.17K$28.93K$10.73K$3.99K
Current assets$847$2.31K$1.93K$4.66K$956$19.85K$22.27K$28.93K$10.73K$3.30K
Total liabilities$42.48K$27.43K$15.66K$3.46K$46.80K$172.44K$208.82K$136.63K$43.73K$105.00K
Current liabilitiesUnavailableUnavailableUnavailableUnavailable$46.80K$172.44K$208.82K$136.63K$43.73K$105.00K
Total equity incl. NCI-$41.64K-$25.12K-$13.73K$1.21K-$45.84K-$152.59K-$186.65K-$107.70K-$33.00K-$101.02K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$17.02K$9.01K$12.57KUnavailable$32.51K$60.80K$101.06K$41.94K$19.65K$64.39K

Cash flow

BURZYNSKI RESEARCH INSTITUTE INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-02-282024-02-292023-02-282022-02-282021-02-282020-02-292019-02-282018-02-282017-02-282016-02-29
Operating cash flow-$388.53K-$523.78K-$249.52K-$325.10K-$394.37K-$530.11K-$477.52K-$319.49K-$314.52KUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$388.07K$524.16K$247.07K$328.42K$394.27K$529.57K$477.72K$319.27K$311.94KUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$684$684

Derived

BURZYNSKI RESEARCH INSTITUTE INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-02-282024-02-292023-02-282022-02-282021-02-282020-02-292019-02-282018-02-282017-02-282016-02-29
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailableUnavailableUnavailable0.12x0.11x0.21x0.25x0.03x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BZYR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-01-13View SEC filing
10-Q · Filed 2025-10-14View SEC filing
10-Q · Filed 2025-07-15View SEC filing
10-K · Filed 2025-05-20View SEC filing
10-Q · Filed 2025-01-13View SEC filing
10-Q · Filed 2024-10-10View SEC filing

Companies in the same industry

ACHV AWHL BMRA CDIO CLDX ICCC IDXX IMDX LNTH MYGN NEOG NTLA

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.